Jennifer Riley, Chief Strategy Officer at Avalo Therapeutics, Inc. (AVTX), sold 2,655 shares at $19.59 ($52K) on 2026-08-11, disclosed to the SEC on 2026-08-12.
Open-market sale of $52k AVTX by Chief Strategy Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.